DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects

Expert Opinion on Drug Metabolism and Toxicology

Volumn 12, Issue 12, 2016, Pages 1407-1417

  Scheen, André J ^a,b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Combined therapy; DPP 4 inhibitor; fixed dose combination; SGLT2 inhibitor; type 2 diabetes mellitus

Indexed keywords

ALOGLIPTIN; CANAGLIFLOZIN; DAPAGLIFLOZIN; DAPAGLIFLOZIN PLUS SAXAGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EMPAGLIFLOZIN; EMPAGLIFLOZIN PLUS LINAGLIPTIN; ERTUGLIFLOZIN; IPRAGLIFLOZIN; LINAGLIPTIN; METFORMIN; METFORMIN PLUS SAXAGLIPTIN; SAXAGLIPTIN; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; TENELIGLIPTIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

CLINICAL FEATURE; DIET; DRUG EFFICACY; DRUG INTERACTION; DRUG SAFETY; EXERCISE; GENITAL TRACT INFECTION; HUMAN; HYPOGLYCEMIA; KETOACIDOSIS; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; PHARMACODYNAMICS; PHARMACOKINETICS; REVIEW; URINARY TRACT INFECTION; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; PATHOPHYSIOLOGY;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84996488587     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1080/17425255.2016.1215427     Document Type: Review

References (65)

1. DeFronzo RA., Banting Lecture. From the triumvirate to the ominous octet:a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773–795.
2. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015:a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015;58:429–442.
3. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm - 2016 executive summary. Endocr Pract. 2016;22:84–113.
4. Barnett AH, Charbonnel B, Moses RG, et al. Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2015;31:1919–1931.
5. Guthrie RM. Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus. Postgrad Med. 2015;127:463–479.
6. Scheen AJ. A review of gliptins for 2014. Exp Opin Pharmacother. 2015;16:43–62.
7. Scheen AJ. Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opin Drug Saf. 2015;14:505–524.
8. Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75:33–59.
9. Scheen AJ. SGLT2 inhibition:efficacy and safety in type 2 diabetes treatment. Exp Opin Drug Safety. 2015;14:1879–1904.
10. Zaccardi F, Webb DR, Htike ZZ, et al. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus:systematic review and network meta-analysis. Diabetes Obesity Metab. 2016;18:783–794.
11. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
12. Scheen AJ. Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial:a critical analysis. Diabetes Metab. 2016;42:71–76.
13. Sharma MD. Potential for combination of dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors for the treatment of type 2 diabetes. Diabetes Obesity Metab. 2015;17:616–621.
14. Abdul-Ghani M. Where does combination therapy with an SGLT2 inhibitor plus a DPP-4 inhibitor fit in the management of type 2 diabetes? Diabetes Care. 2015;38:373–375.
15. Aronson R. Single-pill combination therapy for type 2 diabetes mellitus:linagliptin plus empagliflozin. Curr Med Res Opin. 2015;31:901–911.
16. Woo V. Empagliflozin/linagliptin single-tablet combination:first-in-class treatment option. Int J Clin Pract. 2015;69:1427–1437.
17. Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014;124:509–514.
18. Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124:499–508.
19. Scheen AJ, Paquot N. Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria:a review of the clinical evidence. Diabetes Metab. 2014;40:S4–S11.
20. Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk:results of the EMPA-REG OUTCOME® trial. Eur Heart J. 2016;37:1526–1534.
21. Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus:observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2015;132:e121–e122.
22. Paneni F. DPP-4 inhibitors, heart failure and type 2 diabetes:all eyes on safety. Cardiovasc Diagn Ther. 2015;5:471–478.
23. Williams DM, Stephens JW. Combination therapy with saxagliptin and dapagliflozin for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2015;16:2373–2379.
24. Boulton DW, Kasichayanula S, Keung CFA, et al. Simultaneous oral therapeutic and intravenous (1)(4)C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin. Br J Clin Pharmacol. 2013;75:763–768.
25. Vakkalagadda B, Vetter ML, Rana J, et al. Bioequivalence of saxagliptin/dapagliflozin fixed-dose combination tablets compared with coadministration of the individual tablets to healthy subjects. Pharmacol Res Perspect. 2015;3:e00201.• Pharmacokinetic study demonstrating that saxagliptin/dapagliflozin FDC tablets are bioequivalent to coadministration of the individual components in healthy subjects under fasted conditions, without clinically meaningful effect of food intake.
26. Friedrich C, Metzmann K, Rose P, et al. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers. Clin Ther. 2013;35:A33–42.• Pharmacokinetic study showing the absence of drug–drug interaction between empagliflozin and linagliptin and supporting the coadministration of the two medications without dose adjustments in T2D patients.
27. Kinoshita S, Kondo K. Evaluation of pharmacokinetic and pharmacodynamic interactions of canagliflozin and teneligliptin in Japanese healthy male volunteers. Expert Opin Drug Metab Toxicol. 2015;11:7–14.
28. Hansen L, Iqbal N, Ekholm E, et al. Postprandial dynamics of plasma glucose, insulin, and glucagon in patients with type 2 diabetes treated with saxagliptin plus dapagliflozin add-on to metformin therapy. Endocr Pract. 2014;20:1187–1197.
29. Rosenstock J, Hansen L, Zee P, et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy:a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care. 2015;38:376–383.•• Clinical trial showing greater improvements in glycemic control with triple therapy by the dual addition of saxagliptin and dapagliflozin than dual therapy with the addition of saxagliptin or dapagliflozin alone in T2D patients poorly controlled with metformin.
30. Mathieu C, Ranetti AE, Li D, et al. Randomized, double-blind, phase 3 trial of triple therapy with dapagliflozin add-on to saxagliptin plus metformin in type 2 diabetes. Diabetes Care. 2015;38:2009–2017.• Clinical trial demonstrating that triple therapy with dapagliflozin add-on to saxagliptin plus metformin improves glycemic control and is well tolerated in T2D not well controlled with saxagliptin plus metformin therapy.
31. Matthaei S, Catrinoiu D, Celinski A, et al. Randomized, double-blind trial of triple therapy with saxagliptin add-on to dapagliflozin plus metformin in patients with type 2 diabetes. Diabetes Care. 2015;38:2018–2024.• Clinical trial showing that triple therapy with the addition of saxagliptin to dapagliflozin plus metformin is well tolerated and produces significant improvements in HbA1c in patients with T2D inadequately controlled with dapagliflozin plus metformin.
32. Kim ES, Deeks ED. Empagliflozin/linagliptin:a review in type 2 diabetes. Drugs. 2015;75:1547–1557.
33. Triplitt C, Solis-Herrera C, Cersosimo E, et al. Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus. Expert Opin Pharmacother. 2015;16:2819–2833.
34. Tan X, Hu J, Empagliflozin/linagliptin:combination therapy in patients with type 2 diabetes. Ann Endocrinol (Paris). 2016. published online. doi:10.1016/j.ando.2015.11.003.
35. Rauch T, Graefe-Mody U, Deacon CF, et al. Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus. Diabetes Ther. 2012;3:10.
36. Lewin A, DeFronzo RA, Patel S, et al. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care. 2015;38:394–402.•• Clinical trial in drug-naïve T2D patients showing significantly greater reductions in HbA1c with empagliflozin/linagliptin versus linagliptin 5 mg and empagliflozin 10 mg but not versus empagliflozin 25 mg.
37. DeFronzo RA, Lewin A, Patel S, et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care. 2015;38:384–393.•• Clinical trial in metformin treated T2D patients demonstrating that combinations of empagliflozin/linagliptin (10/5 mg and 25/5 mg) as second-line therapy significantly reduce HbA1c compared with the individual components and are well tolerated.
38. Plosker GL. Canagliflozin:a review of its use in patients with type 2 diabetes mellitus. Drugs. 2014;74:807–824.
39. Fulcher G, Matthews DR, Perkovic V, et al. Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2016;18:82–91.
40. Inagaki N, Kondo K, Yoshinari T, et al. Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes:a 52-week open-label study. J Diabetes Investig. 2015;6:210–218.
41. Kadowaki T, Marubayashi F, Yokota S, et al. Safety and efficacy of teneligliptin in Japanese patients with type 2 diabetes mellitus:a pooled analysis of two Phase III clinical studies. Expert Opin Pharmacother. 2015;16:971–981.
42. Scott LJ. Teneligliptin:a review in type 2 diabetes. Clin Drug Investig. 2015;35:765–772.
43. Plosker GL. Sitagliptin:a review of its use in patients with type 2 diabetes mellitus. Drugs. 2014;74:223–242.
44. Kasichayanula S, Liu X, Shyu WC, et al. Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes Obes Metab. 2011;13:47–54.
45. Smulders RA, Zhang W, Veltkamp SA, et al. No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects. Diabetes Obes Metab. 2012;14:937–943.
46. Kasahara N, Fukase H, Ohba Y, et al. A pharmacokinetic/pharmacodynamic drug-drug interaction study of tofogliflozin (a new SGLT2 inhibitor) and selected anti-type 2 diabetes mellitus drugs. Drug Res. 2016;66:74–81.
47. Kumar V, Sahasrabudhe V, Matschke K, et al. Lack of a pharmacokinetic interaction between ertugliflozin and sitagliptin or metformin in healthy subjects. Clin Pharmacol Ther. 2016;99:S47. (Abstract).
48. Jabbour SA, Hardy E, Sugg J, et al. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin:a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care. 2014;37:740–750.
49. Eldor R, Pratley R, Golm G, et al. Effect of ertugliflozin plus sitagliptin on glycemic control vs. either treatment alone in subjects with T2DM inadequately controlled with metformin. Oral presentation at the 76th Scientific Sessions of the American Diabetes Association; 2016 Jun 10–14; New Orleans. Abstract number:125-LB.
50. Zambrowicz B, Ding ZM, Ogbaa I, et al. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes. Clin Ther. 2013;35:273–85 e7.
51. Taylor SI, Blau JE, Rother KI. Perspective:SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab. 2015;100:2849–2852.
52. Li L, Li S, Deng K, et al. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes:systematic review and meta-analysis of randomised and observational studies. BMJ. 2016;352:i610.
53. Scheen AJ, Radermecker RP. Addition of incretin therapy to metformin in type 2 diabetes. Lancet. 2010;375:1410–1412.
54. Scheen AJ, Paquot N. Gliptin versus a sulphonylurea as add-on to metformin. Lancet. 2012;380:450–452.
55. Scheen AJ. SGLT2 versus DPP4 inhibitors for type 2 diabetes. Lancet Diabetes Endocrinol. 2013;1:168–170.
56. Thayer S, Chow W, Korrer S, et al. Real-world evaluation of glycemic control among patients with type 2 diabetes mellitus treated with canagliflozin versus dipeptidyl peptidase-4 inhibitors. Curr Med Res Opin. 2016;32:1087–1096.
57. Brietzke SA. Oral antihyperglycemic treatment options for type 2 diabetes mellitus. Med Clin North Am. 2015;99:87–106.
58. Scheen AJ. Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes. Clin Pharmacokinet. 2015;54:1–21.
59. Scheen AJ. Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease. Clin Pharmacokinet. 2015;54:691–708.
60. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016. [Epub ahead of print].
61. Scheen AJ, Charbonnel B. Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes:a critical reappraisal. Diabetes Metab. 2014;40:176–185.
62. Scheen AJ. Precision medicine:the future in diabetes care? Diabetes Res Clin Pract. 2016;117:12–21.
63. Charokopou M, McEwan P, Lister S, et al. Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to metformin in the treatment of type 2 diabetes mellitus from a UK healthcare system perspective. BMC Health Serv Res. 2015;15:496.
64. Geng J, Yu H, Mao Y, et al. Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes. Pharmacoeconomics. 2015;33:581–597.
65. Lopez JMS, Macomson B, Ektare V, et al. Evaluating drug cost per response with SGLT2 inhibitors in patients with type 2 diabetes mellitus. Am Health Drug Benefits. 2015;8:309–318.